Skip to main content
. 2019 Mar 15;98(13):e14135. doi: 10.1097/MD.0000000000014135

Table 3.

Grade 3/4 treatment-related adverse events, analyzed by type of EGFR-TKIs combination and by cancer type.

3.3.